NASDAQ:PEPG PepGen (PEPG) Stock Price, News & Analysis $16.47 -0.21 (-1.26%) (As of 10:02 AM ET) Add Compare Share Share Today's Range$16.40▼$16.7150-Day Range$11.68▼$18.1452-Week Range$3.72▼$18.72Volume6,343 shsAverage Volume110,608 shsMarket Capitalization$533.96 millionP/E RatioN/ADividend YieldN/APrice Target$23.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get PepGen alerts: Email Address PepGen MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside37.9% Upside$23.00 Price TargetShort InterestHealthy1.37% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.41Based on 5 Articles This WeekInsider TradingSelling Shares$312,228 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.87) to ($2.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.44 out of 5 starsMedical Sector491st out of 896 stocksPharmaceutical Preparations Industry227th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingPepGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePepGen has only been the subject of 2 research reports in the past 90 days.Read more about PepGen's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.37% of the float of PepGen has been sold short.Short Interest Ratio / Days to CoverPepGen has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in PepGen has recently decreased by 10.88%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPepGen does not currently pay a dividend.Dividend GrowthPepGen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PEPG. Previous Next 1.9 News and Social Media Coverage News SentimentPepGen has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for PepGen this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PepGen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $312,228.00 in company stock.Percentage Held by InsidersOnly 4.60% of the stock of PepGen is held by insiders.Percentage Held by Institutions58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PepGen's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PepGen are expected to grow in the coming year, from ($2.87) to ($2.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PepGen is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PepGen is -5.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPepGen has a P/B Ratio of 3.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about PepGen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Digital Mavericks Media1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income every month.Click here to check it out. About PepGen Stock (NASDAQ:PEPG)PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.Read More PEPG Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PEPG Stock News HeadlinesJune 27, 2024 | insidertrades.comInsider Selling: PepGen Inc. (NASDAQ:PEPG) Insider Sells 9,260 Shares of StockJuly 1, 2024 | americanbankingnews.comPepGen (NASDAQ:PEPG) Trading 5.1% Higher July 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.June 30, 2024 | americanbankingnews.comPepGen (NASDAQ:PEPG) Sees Strong Trading VolumeJune 29, 2024 | americanbankingnews.comPepGen (NASDAQ:PEPG) Trading Down 4.7% Following Insider SellingJune 27, 2024 | americanbankingnews.comPepGen Inc. (NASDAQ:PEPG) Insider Michelle L. Mellion Sells 9,260 Shares of StockJune 11, 2024 | businesswire.comPepGen Announces Executive Team PromotionsMay 22, 2024 | finance.yahoo.comWe're Not Very Worried About PepGen's (NASDAQ:PEPG) Cash Burn RateJuly 5, 2024 | Behind the Markets (Ad)"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Pharma's biggest blockbuster yet." Bank of America predicts it will be the world's first "$100 billion dollar a year drug." And Morgan Stanley predicts 250 million prescriptions will be written each year.May 20, 2024 | seekingalpha.comThe Prognosis For PepGenMay 15, 2024 | markets.businessinsider.comBuy Rating on PepGen Inc. Backed by PGN-EDO51’s Efficacy and Safety ProfileMay 14, 2024 | msn.comPEPG Stock Earnings: PepGen Beats EPS for Q1 2024May 14, 2024 | globenewswire.comPepGen Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsMay 9, 2024 | msn.comHHS panel to vote in Nov. on DMD screening for newbornsMay 2, 2024 | markets.businessinsider.comBuy Rating on Sarepta Therapeutics Backed by Elevidys’s Market Expansion and FDA Approval ProspectsApril 26, 2024 | markets.businessinsider.comOptimistic Outperform Rating on Sarepta Therapeutics Amid Strong Elevidys Demand and Potential Label ExpansionApril 12, 2024 | insidermonkey.comHedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and MoreMarch 13, 2024 | marketwatch.comPepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease DesignationsMarch 13, 2024 | globenewswire.comPepGen to Participate in Upcoming Investor ConferencesMarch 13, 2024 | markets.businessinsider.comPepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51March 13, 2024 | globenewswire.comPepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyMarch 12, 2024 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on PepGen Inc. (PEPG)March 9, 2024 | seekingalpha.comPepGen, Inc. (PEPG) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | investorplace.comPEPG Stock Earnings: PepGen Beats EPS for Q4 2023March 6, 2024 | investing.comPepGen's DMD therapy advances to phase 2 trial in the UKMarch 6, 2024 | globenewswire.comPepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate DevelopmentsMarch 4, 2024 | globenewswire.comPepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophySee More Headlines Receive PEPG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today7/05/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PEPG CUSIPN/A CIK1835597 Webwww.pepgen.com Phone781-797-0979FaxN/AEmployees64Year FoundedN/APrice Target and Rating Average Stock Price Target$23.00 High Stock Price Target$26.00 Low Stock Price Target$20.00 Potential Upside/Downside+39.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-78,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-57.32% Return on Assets-46.14% Debt Debt-to-Equity RatioN/A Current Ratio15.78 Quick Ratio15.78 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.55 per share Price / Book3.62Miscellaneous Outstanding Shares32,420,000Free Float30,926,000Market Cap$533.96 million OptionableNot Optionable Beta1.73 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. James G. McArthur Ph.D. (Age 62)President, CEO, Treasurer, Secretary & Director Comp: $834.98kMr. Noel P. Donnelly M.B.A. (Age 54)Chief Financial Officer Comp: $650.17kMr. Niels Svenstrup Ph.D. (Age 54)Senior Vice President of Chemistry, Manufacturing & Control Comp: $455.15kDr. Michael Gait Ph.D.Founder & Scientific Advisory Board MemberMs. Emiko BryantChief of StaffMr. Kyle BreidenstineVP of Finance & ControllerMore ExecutivesKey CompetitorsIndiviorNASDAQ:INDVJanux TherapeuticsNASDAQ:JANXProtagonist TherapeuticsNASDAQ:PTGXAmneal PharmaceuticalsNASDAQ:AMRXVera TherapeuticsNASDAQ:VERAView All CompetitorsInsiders & InstitutionsMichelle L. MellionSold 37 sharesTotal: $668.59 ($18.07/share)Michelle L. MellionSold 9,260 sharesTotal: $168,439.40 ($18.19/share)Michelle L. MellionSold 500 sharesTotal: $9,020.00 ($18.04/share)RA Capital Management L.P.Bought 2,557,593 shares on 5/17/2024Ownership: 32.972%Artal Group S.A.Bought 200,000 shares on 5/17/2024Ownership: 0.617%View All Insider TransactionsView All Institutional Transactions PEPG Stock Analysis - Frequently Asked Questions Should I buy or sell PepGen stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PepGen in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PEPG shares. View PEPG analyst ratings or view top-rated stocks. What is PepGen's stock price target for 2024? 2 brokerages have issued 12-month target prices for PepGen's shares. Their PEPG share price targets range from $20.00 to $26.00. On average, they expect the company's stock price to reach $23.00 in the next year. This suggests a possible upside of 37.9% from the stock's current price. View analysts price targets for PEPG or view top-rated stocks among Wall Street analysts. How have PEPG shares performed in 2024? PepGen's stock was trading at $6.80 at the beginning of the year. Since then, PEPG stock has increased by 145.3% and is now trading at $16.68. View the best growth stocks for 2024 here. When is PepGen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our PEPG earnings forecast. How were PepGen's earnings last quarter? PepGen Inc. (NASDAQ:PEPG) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.11. What ETFs hold PepGen's stock? ETFs with the largest weight of PepGen (NASDAQ:PEPG) stock in their portfolio include Morningstar US Small Growth (MSGR).iShares Neuroscience and Healthcare ETF (IBRN). When did PepGen IPO? PepGen (PEPG) raised $126 million in an initial public offering (IPO) on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of PepGen? Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PEPG) was last updated on 7/5/2024 by MarketBeat.com Staff From Our Partners50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredBiden to drop out; finish out his term?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in...Paradigm Press | SponsoredObama’s DNC coupAs we approach the Democratic National Convention in August... many sense a Biden swap-out is looming. In f...Stansberry Research | Sponsored1k a day while computer does all work?What I discovered is now helping me take in more than 1k a day. It's like a "magic key" to passive income ...Digital Mavericks Media | SponsoredGrab Your Free Bitcoin Today!And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PepGen Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PepGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PEPG Stock Alerts